Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes...
Saved in:
Main Authors: | I. N. Dyakov (Author), S. K. Zyryanov (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020) -
The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021) -
Economic perspectives for effective control of diabetes mellitus type 2 with fixed combination of basal insulin analog and GLP-1 agonist
by: S. K. Zyryanov, et al.
Published: (2019) -
Pharmacoeconomics expediency of application of the combined preparation of Vezomni in comparison with a combination of Tamsulosin and Solifenacin in the form of monopreparations
by: S. K. Zyryanov, et al.
Published: (2018) -
Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021)